Central Trust CO Neurocrine Biosciences Inc Transaction History
Central Trust CO
- $3.97 Billion
- Q1 2025
A detailed history of Central Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Central Trust CO holds 76 shares of NBIX stock, worth $8,150. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76
Previous 86
11.63%
Holding current value
$8,150
Previous $11,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding NBIX
# of Institutions
653Shares Held
95.5MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.52 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.09 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$525 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$323 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$272 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...